BOSTON, April 25, 2025 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: PYXS), a clinical-stage company developing next-generation ADC therapeutics for difficult-to-treat cancers, announced today ...
Pyxis Oncology (NASDAQ:PYXS) is down ~38% in after-hours trading Wednesday after posting preliminary phase 1 data on PYX-201, an antibody-drug conjugate for solid tumors. The data presented was in six ...
BOSTON, March 27, 2024 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: PYXS), a clinical stage company focused on developing next generation therapeutics to target difficult-to-treat cancers, ...
Pyxis Oncology is developing next-generation therapeutics, including antibody-drug conjugates and immuno-oncology programs, to target solid tumors resistant to current treatments. PYXS's lead product ...
SAN DIEGO, June 11, 2013 /PRNewswire/ -- CareFusion Corp. (NYSE: CFN), a leading, global medical technology company, today announced a new contract with The University of Texas MD Anderson Cancer ...
Pyxis Oncology had cash and cash equivalents, including restricted cash and short-term investments of $157.2 million. Pyxis says that its current cash, cash equivalents, and short-term investments ...
SAN DIEGO, June 24, 2013 /PRNewswire/ -- CareFusion Corp. (NYSE: CFN), a leading, global medical technology company, today announced that 14 additional hospitals across the country have adopted the ...
It’s been a good week for investors of Pyxis Oncology (NASDAQ:PYXS), to say the least. Over the past 4 sessions Pyxis shares have gained 170%, bringing the year-to-date haul to a mighty 340%. This ...
CAMBRIDGE, Mass., March 18, 2021 (GLOBE NEWSWIRE) -- Pyxis Oncology (“Pyxis” or the "Company”) today announced that it has entered into a worldwide license agreement with Pfizer Inc. (NYSE:PFE) for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback